Introduction: Who Should Undergo Diagnostics

If you develop a painful skin wound that appears suddenly and grows rapidly, it is important to seek medical attention promptly. Pyoderma gangrenosum typically begins as a small bump, pustule, or what might look like an insect bite, but within days it can transform into a large, painful open sore. The speed at which these wounds expand is unusual and should raise concern.^[1]

You should particularly consider seeking diagnostic evaluation if you have certain underlying health conditions. People with inflammatory bowel disease—such as ulcerative colitis or Crohn’s disease—are at higher risk of developing pyoderma gangrenosum. Similarly, those with rheumatoid arthritis, blood disorders like leukemia or myelodysplasia, or other autoimmune conditions should be alert to unusual skin wounds that don’t heal normally.^[2]

It is also advisable to seek diagnostics if a wound appears after trauma to the skin or following surgery. Pyoderma gangrenosum can develop at sites of injury—a phenomenon called pathergy. Sometimes these ulcers appear around surgical openings, such as stoma sites after bowel surgery. If a surgical wound begins to break down rapidly or doesn’t respond to standard wound care, it warrants further investigation.^[3]

Anyone experiencing a skin ulcer that doesn’t improve with normal treatment, or that seems to worsen despite care, should consult a healthcare professional. Early and correct diagnosis is crucial because misdiagnosis can lead to inappropriate treatments that may actually make the condition worse.^[10]

Classic Diagnostic Methods

Diagnosing pyoderma gangrenosum is particularly challenging because there is no specific test that can definitively confirm the condition. Instead, doctors must make the diagnosis by carefully examining the patient’s symptoms, medical history, and by ruling out other conditions that can cause similar-looking wounds.^[10]

The diagnostic process typically begins with a thorough conversation between the healthcare professional and the patient. The doctor will ask about when the wound first appeared, how quickly it has grown, and whether there was any injury or trauma to the area beforehand. They will also inquire about other health conditions you may have, particularly autoimmune diseases, inflammatory bowel disease, or blood disorders, as these are frequently associated with pyoderma gangrenosum.^[1]

During a physical examination, doctors look for distinctive features of pyoderma gangrenosum. The ulcers typically have a characteristic appearance: they are often large and painful, with raised edges that have a purple or blue color. This distinctive border is sometimes described as “undermined” or “overhanging.” The ulcers most commonly appear on the legs, though they can develop anywhere on the body.^[4]

Because pyoderma gangrenosum looks similar to many other conditions—including infections, injuries, blood vessel inflammation, and even some types of cancer—doctors must systematically rule out these alternative diagnoses. This process of elimination is a critical part of reaching the correct diagnosis.^[3]

Skin Biopsy

A skin biopsy is often performed as part of the diagnostic workup. During this procedure, a small sample of skin tissue is removed from the edge of the ulcer and examined under a microscope in a laboratory. While pyoderma gangrenosum does not have a specific appearance under the microscope, the biopsy is extremely helpful in ruling out other causes of ulceration, such as infection, cancer, or blood vessel disorders.^[10]

What pathologists typically see in pyoderma gangrenosum tissue samples is an abundance of white blood cells called neutrophils. This finding supports the diagnosis, although it is not unique to pyoderma gangrenosum. The biopsy helps exclude other conditions that might mimic the disease.^[7]

Wound Culture and Swab Tests

To rule out infection, doctors may take a swab from the wound to test for bacteria or other microorganisms. Even though pyoderma gangrenosum is not caused by infection, the ulcers can sometimes become secondarily infected. Testing helps differentiate between pyoderma gangrenosum and wounds caused primarily by bacterial infection.^[7]

Blood Tests

Blood tests are frequently ordered to help identify underlying conditions that are associated with pyoderma gangrenosum and to exclude other diseases. These tests might include a complete blood count, markers of inflammation, and tests for autoimmune conditions or blood disorders. Since approximately half of people with pyoderma gangrenosum have another systemic disease, blood work helps paint a fuller picture of the patient’s health.^[2]

In some cases, doctors may order tests for specific antibodies or proteins that indicate inflammatory or autoimmune activity. While these tests cannot diagnose pyoderma gangrenosum directly, they can identify conditions that are commonly linked to it, such as rheumatoid arthritis or inflammatory bowel disease.^[8]

Imaging Studies

Depending on the clinical situation, imaging studies such as chest X-rays may be performed. These tests are not used to diagnose pyoderma gangrenosum itself but rather to look for associated conditions or complications. For example, some patients with pyoderma gangrenosum can have inflammation in other organs, and imaging can help detect these.^[10]

Examination of the Colon

If inflammatory bowel disease is suspected, a colonoscopy or sigmoidoscopy may be recommended. Since pyoderma gangrenosum is associated with ulcerative colitis in 5 to 12 percent of cases and with Crohn’s disease in 1 to 2 percent of cases, examining the bowel can help identify underlying intestinal inflammation.^[2]

Referral to a Specialist

Because pyoderma gangrenosum is rare and difficult to diagnose, patients are often referred to a dermatologist—a doctor who specializes in skin conditions. Dermatologists have more experience recognizing the distinctive features of pyoderma gangrenosum and can coordinate the necessary tests to reach an accurate diagnosis. Early referral to a specialist can help reduce delays in diagnosis and prevent inappropriate treatments.^[10]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or approaches to managing pyoderma gangrenosum. To ensure that participants truly have the condition and can be safely included in the study, rigorous diagnostic criteria are applied during the screening process.

Recent efforts to standardize the diagnosis of pyoderma gangrenosum have led to the development of specific diagnostic criteria. One widely recognized system requires meeting one major criterion along with at least four out of eight minor criteria. This approach was developed through expert consensus and has high sensitivity and specificity for diagnosing pyoderma gangrenosum.^[14]

The major criterion is that a tissue biopsy must show infiltration by neutrophils. This means that when skin tissue is examined under a microscope, there should be evidence of these particular white blood cells accumulating in the tissue.^[14]

The eight minor criteria include: exclusion of infection through appropriate testing; a history of pathergy (where skin injury triggers new lesions); a history of inflammatory bowel disease or inflammatory arthritis; a history of a “sentinel” event such as a bump or pustule that preceded the ulcer; purple or bluish discoloration at the ulcer’s edge; the presence of undermining borders around the ulcer; pain that is out of proportion to what would be expected; and multiple ulcerations.^[14]

For clinical trial enrollment, potential participants typically undergo a comprehensive baseline evaluation. This includes documentation of the ulcer’s size, location, and appearance through photographs and measurements. The number of ulcers present is carefully recorded, as trials may have specific criteria about the severity of disease required for participation.

Blood tests are standard in clinical trial screening to assess overall health, measure inflammatory markers, and identify any underlying conditions. These tests help determine if a person is healthy enough to participate and establish baseline values that can be compared during treatment. Common blood tests include complete blood counts, liver and kidney function tests, and inflammatory markers such as C-reactive protein or fecal calprotectin (a marker of bowel inflammation).^[14]

Microbiological testing is performed to rule out active infections. Wound swabs or cultures ensure that the ulcers are not caused by bacteria, fungi, or other microorganisms. This is important both for diagnostic accuracy and for patient safety, as immunosuppressive treatments being tested in trials could be dangerous for someone with an active infection.

Depending on the trial’s focus, additional imaging studies may be required. For example, if a trial is studying patients with both pyoderma gangrenosum and inflammatory bowel disease, intestinal ultrasound or colonoscopy might be used to document the severity of bowel inflammation at the start of the study.^[14]

Many clinical trials for pyoderma gangrenosum also require documentation of previous treatments that have been tried and whether they were effective. This information helps researchers understand whether the patient has treatment-resistant disease and whether they meet the specific inclusion criteria for the study.

Patient-reported outcomes are increasingly used in clinical trials. These include questionnaires about pain levels, the impact of the disease on quality of life, and functional limitations. These assessments help capture how the disease affects daily living from the patient’s perspective and provide a way to measure improvement beyond just the physical healing of ulcers.

Some trials may also use standardized scoring systems to measure disease severity and activity. These systems take into account factors such as the size and number of ulcers, the presence of pain, and how rapidly the ulcers are growing or healing. Having consistent ways to measure disease helps researchers compare results across different studies and patients.